Prospective, Multicenter, Clinical Evaluation of Point-of-Care Matrix Metalloproteinase-9 Test for Confirming Dry Eye Disease

Sambursky, Robert; Davitt, William F.; Friedberg, Murray; Tauber, Shachar

doi:10.1097/ico.0000000000000175

Cited by 86 publications

(76 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Standard testing revealed a sensitivity of 86% and specificity of 97% using combined diagnostic criteria of dry-eye tests (OSDI > = 13, Schirmer II < 10 mm, TBUT < 10 s, and staining > = 1).There was also a good correlation of MMP-9 expression with the different severity levels of the dry-eye condition (DEWS severity criteria) (82). More recently, Schargus et al have evaluated the performance of MMP-9 using InflammaDry (and confirmed by ELISA) and tear film osmolarity (TFO) tests in a cohort of 20 elderly patients with potential dry-eye disease, finding a positive association only between MMP-9 and corneal staining.…”

Section: Accepted Manuscriptmentioning

confidence: 79%

Human tear proteomics and peptidomics in ophthalmology: Toward the translation of proteomic biomarkers into clinical practice

Azkargorta

Soria

Acera

et al. 2017

Journal of Proteomics

View full text Add to dashboard Cite

Section: Accepted Manuscriptmentioning

confidence: 79%

Human tear proteomics and peptidomics in ophthalmology: Toward the translation of proteomic biomarkers into clinical practice

Azkargorta

Soria

Acera

et al. 2017

Journal of Proteomics

View full text Add to dashboard Cite

“…Using a point-of-care lateral flow immunoassay (InflammaDry ® ; Rapid Pathogen Screening, Sarasota, FL, USA), which detects both pro-and active MMP-9 at tear concentrations ≥40 ng/mL, elevated tear MMP-9 was found to have high sensitivity and specificity with clinical diagnosis of dry eye in two studies, and in another study, a positive result was significantly correlated with severity of irritation symptoms and ocular surface dye staining, tear break-up time and systemic autoimmune disease, particularly SS. [67][68][69] Using the same assay, Lanza et al found only 39% of subjects with symptoms of dry eye had a positive MMP-9 assay and there was no difference in the profile of signs and symptoms between MMP-9-positive and …”

Section: Correlations Between Mmp-9 and Severitymentioning

confidence: 99%

Matrix metalloproteinase-9 in the pathophysiology and diagnosis of dry eye syndrome

Pflugfelder¹,

Bian²,

Paiva³

2017

MNM

View full text Add to dashboard Cite

Dry eye and tear dysfunction are common ocular disorders that cause cornea barrier disruption resulting in a poorly lubricated and irregular cornea epithelium, eye irritation and blurred vision. Increased levels and activities of matrix metalloproteinases (MMPs), particularly MMP-9, have been detected in the tears and ocular surface epithelial and inflammatory cells in dry eye. MMPs have been found to participate in disruption of tight junctions in the apical cornea epithelium leading to their accelerated desquamation and barrier disruption. This review summarizes evidence showing the contribution of MMPs to dry eye pathogenesis and their roles as biomarkers and therapeutic targets. Keywords: matrix metalloproteinase, dry eye, keratitis sicca, cornea, barrier function, Sjögren syndrome Dry eye overviewDry eye and tear dysfunction are common ocular disorders that cause cornea barrier disruption resulting in a poorly lubricated and irregular cornea epithelium, eye irritation and blurred vision. It affects millions of people worldwide and is one of the most frequent conditions for which patients seek eye care.1 Aging and female sex are significant risk factors for dry eye which increases in prevalence around the fifth decade, with further increase every decade thereafter.2-13 Prevalence of dry eye varies from 2% to 50%, depending on the population studied and the diagnostic criteria for dry eye (symptom questionnaire vs. objective signs). [1][2][3]6,7,[9][10][11][14][15][16][17][18][19][20][21][22][23] There is scarce information about the natural history of dry eye, but there is a recognized disconnection between signs and symptoms; patients tend to be more symptomatic at early stages.24,25 Dry eye causes corneal irregularity [26][27][28] and decreases functional vision by altering contrast sensitivity [29][30][31] and, therefore, decreases quality of life with a significant burden on the individual as well as the society. 23,[32][33][34][35] A meta-analysis of 22 published studies showed increased odds ratio for depression and anxiety in patients with ocular Sjögren syndrome (SS). 36 There is increased evidence that dry eye is an inflammatory disease, and this review will focus on matrix metalloproteinases (MMPs) and their role in the pathogenesis of dry eye. Cornea barrier disruption is a feature of dry eyeAs the principal lens of the eye, the cornea has unique features to maintain its transparency and smooth surface that include a lack of blood vessels and a multilayered stratified, non-cornifying epithelium. The differentiated apical epithelial cells produce

show abstract

“…Indeed, MMP-9 has been proposed as a marker for severe dry eye 21. Although the InflammaDry test demonstrated a high positive and negative agreement for confirming suspected dry eye disease,22 none of the previous studies have evaluated the performance of InflammaDry in post-LASIK dry eyes. Indeed, not all cases with dry eyes are associated with significant inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, not all cases with dry eyes are associated with significant inflammation. Sambursky et al 22 examined only symptomatic patients and showed that 61% of symptomatic patients by OSDI actually had a positive confirmatory test using Schirmer test, TBUT or staining, and 81% of those patients with any positive confirmatory test showed elevated MMP-9. The primary utility for InflammaDry should not be simply as a diagnostic tool for dry eye but a tool for the presence of inflammation related to dry eye.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of point-of-care test for elevated tear matrix metalloproteinase 9 in post-LASIK dry eyes

Chan

et al. 2015

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

Prospective, Multicenter, Clinical Evaluation of Point-of-Care Matrix Metalloproteinase-9 Test for Confirming Dry Eye Disease

Cited by 86 publications

References 38 publications

Human tear proteomics and peptidomics in ophthalmology: Toward the translation of proteomic biomarkers into clinical practice

Human tear proteomics and peptidomics in ophthalmology: Toward the translation of proteomic biomarkers into clinical practice

Matrix metalloproteinase-9 in the pathophysiology and diagnosis of dry eye syndrome

Evaluation of point-of-care test for elevated tear matrix metalloproteinase 9 in post-LASIK dry eyes

Contact Info

Product

Resources

About